A Pune court has rejected an application seeking injunction against the use of `Covishield' as brandname by the vaccine-maker Serum Institute of India (SII).
SII is producing a coronavirus vaccine named Covishield, co-developed by the University of Oxford and British-Swedish company AstraZeneca. The Indian government has purchased 11 million doses of Covishield vaccine.
On January 4, Cutis-Biotech, a pharmaceutical firm, filed a suit in the civil court claiming it was a prior user of the brand name Covishield, and sought to restrain SII from using the name.
SII had told the court that the two companies operate in different product categories and there is no scope for confusion over the trademark.